Belite Bio Receives Approval To Initiate Tinlarebant Phase 3 Clinical Trial For Ga In
Australia
Portfolio Pulse from Benzinga Newsdesk
Belite Bio, Inc (NASDAQ:BLTE) has received approval from the Human Research Ethics Committee (HREC) to initiate the Phase 3 clinical trial of Tinlarebant for Geographic Atrophy in Australia. Tinlarebant is intended to slow disease progression in patients with Stargardt Disease and Geographic Atrophy in advanced Dry Age-related Macular Degeneration. The drug has been granted Fast Track Designation and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in both the U.S. and Europe.
August 04, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio's approval to initiate Phase 3 clinical trial of Tinlarebant in Australia could potentially boost the company's stock as it marks a significant step in the drug's development process.
The approval for the Phase 3 clinical trial of Tinlarebant in Australia is a significant milestone for Belite Bio. This could potentially attract more investors, leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100